The mission of Taiho Oncology, Inc. (Taiho) is to improve the lives of patients with cancer, their families and their caregivers. The company specializes in orally administered anti-cancer agents and has a growing pipeline of antimetabolic and selectively targeted anti-cancer agents. A subsidiary of Taiho Pharmaceutical Co., Ltd., Taiho markets its medicines for a range of tumor types in the U.S. and oversees its parent company’s European and Canadian operations in Zug, Switzerland and Oakville, Ontario, Canada. For more information, visit www.taihooncology.com